Selecta Biosciences (SELB) Misses Q2 EPS by 24c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. FTNT
5. EBAY
6. CMG
7. TENB
8. BIIB
9. KLAC
10. ETSY

Go back to Selecta Biosciences (SELB) Misses Q2 EPS by 24c

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

August 6, 2020 7:30 AM EDT

Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research license and option agreement with Sarepta for the use of the ImmTOR immune tolerance platform in Sareptas gene therapy programs in certain neuromuscular diseasesGene therapy program in MMA in collaboration with AskBio on track to enter the clinic in the first half of 2021; preliminary data expected in the second half of 2021Phase 3 clinical program of SEL-212 to commence with Sobi in Q3 2020; on track to... More